TOLAZAMIDE SUMMARY
Tolazamide is an oral blood-glucose-lowering drug of the sulfonylurea class. Tolazamide is a white or creamy-white powder very slightly soluble in water and slightly soluble in alcohol.
Tolazamide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
|
|
NEWS HIGHLIGHTS
Clinical Trials Related to Tolazamide
Incretin-based Drugs and Acute Pancreatitis [Completed]
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2
diabetes) taken either alone or in combination with other anti-diabetic drugs are associated
with an increased risk of acute pancreatitis (AP) compared to other combinations of oral
hypoglycemic agents (OHA).
The investigators will carry out separate population based cohort studies using
administrative health databases in six jurisdictions in Canada, the US, and the UK. Cohorts
will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs
entered the market, with follow-up until hospitalization for AP. The results from the
separate sites will be combined to provide an overall assessment of the risk of AP in users
of incretin-based drugs and by class of incretin-based drugs.
Incretin-based Drugs and Pancreatic Cancer [Completed]
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2
diabetes) taken either alone in or combination with other anti-diabetic drugs are associated
with an increased risk of pancreatic cancer (PC) compared to sulfonylureas.
The investigators will carry out separate population based cohort studies using
administrative health databases in five jurisdictions in Canada, the US, and the UK. Cohorts
will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs
entered the market, with follow-up until hospitalization for PC. The results from the
separate sites will be combined to provide an overall assessment of the risk of PC in users
of incretin-based drugs and by class of incretin-based drugs.
Incretin-based Drugs and the Risk of Heart Failure [Completed]
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2
diabetes) taken either alone or in combination with other anti-diabetic drugs are associated
with an increased risk of heart failure (HF) compared to other combinations of oral
hypoglycemic agents (OHA).
The investigators will carry out separate population based cohort studies using
administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts
will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs
entered the market, with follow-up until hospitalization for HF. Analyses will be done
separately for groups of patients with and without prior HF. The results from the separate
sites will be combined to provide an overall assessment of the risk of HF in users of
incretin-based drugs and by class of incretin-based drugs.
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies [Completed]
This was a 10-week, placebo-controlled, randomized study to investigate the effect of
injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance
or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes
therapies.
|
|
Page last updated: 2009-12-15
|